Abstract
Background: India has the notorious distinction of being the country with maximum incidence of MDRTB. Nuh district in North India has one of the highest incidence of MDRTB in India. We studied the treatment outcome of diagnosed Multi-Drug Resistant tuberculosis in this district between January 2016 to December 2016, followed upto December 2019.
Methods: This was a Observational Cohort study, patients were diagnosed by DST and CBNAAT. As per DOTS-Plus regimen of RNTCP- Intensive Phase consisted of 6 drugs (kanamycin, fluroquinolones, ethionamide, cycloserine, pyrazinamide, ethambutol) and Continuation Phase of 4 drugs (ofloxacin, ethionamide, cycloserine and ethambutol). The minimum period of treatment was 24 months, extended upto 28 months.
A total of 120 patients were diagnosed with MDRTB. Mean age of patients were 35+/-3.5 years. 24 (20%) were household contacts. 6 (5%) had primary MDRTB.30(25%) patients failed to sputum convert and were declared XDR TB and were started on treatment.25(21%) were untraceable and 15(12.5%) died during course of treatment. 59% were declared cured after treatment.
Conclusion: DOTS-Plus strategy is an effective one, but lot needs to be achieved further given the fact that more than one in five patients were untraceable. Given the active age of affliction and stigma associated with the disease, multisectoral and cost-effective measures need to be implemented to curb the epidemic.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3347.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021
